Abrocitinib

CHEMBL3655081 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
323.4 g/mol
LogP
1.7
Phase
4

An oral medication that works inside immune cells by blocking a signaling enzyme called JAK1, reducing the inflammatory signals that drive itching and skin inflammation in eczema. It is approved for moderate-to-severe atopic dermatitis in adults and adolescents when other treatments have not worked well enough. Patients should avoid live vaccines while taking it and should be aware of a small increased risk of serious infections, blood clots, and cardiovascular events.

Khối lượng phân tử

323,4200 g/mol

LogP

1,70

TPSA

99,40 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Cơ chế tác dụng

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1

InChI

InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)/t10-,11+

Molecular Formula

C14H21N5O2S

HBD / HBA

2 / 6

Liên kết có thể quay

6

Nguyên tử nặng

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

An oral medication that works inside immune cells by blocking a signaling enzyme called JAK1, reducing the inflammatory signals that drive itching and skin inflammation in eczema. It is approved for moderate-to-severe atopic dermatitis in adults and adolescents when other treatments have not worked well enough. Patients should avoid live vaccines while taking it and should be aware of a small increased risk of serious infections, blood clots, and cardiovascular events.

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Yes, Abrocitinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3655081. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 78323835. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.